Company Announcement no. 20/2012
Hørsholm, Denmark, 13 November 2012
To: NASDAQ OMX Copenhagen A/S
Major shareholder announcements
Pursuant to section 29 of the Danish Securities Trading Act, Veloxis Pharmaceuticals A/S (OMX: VELO) hereby makes public, that the company has received the following major shareholder announcements:
For more information, please contact:
Veloxis Pharmaceuticals A/S
Bill Polvino, President & CEO
Mobile: +1 917 647 9107
Johnny Stilou, EVP, Chief Financial Officer
Mobile: +45 21 227 227
For further information, please visit www.veloxis.com.
About Veloxis Pharmaceuticals
Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis is a specialty pharmaceutical company. The company's lead product candidate is LCP-Tacro for immunosuppression, specifically organ transplantation. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability at low scale up costs. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market that is commercialized through partner Santarus, Inc. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.